Skip to main content

Advertisement

SpringerLink
Log in

Controversial Issues in Current Treatment of Chronic HBV Infection

  • Hepatitis B (J Lim, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

The management of patients with progressive chronic hepatitis B infection (CHB) has undergone dramatic changes in the last decade, with the introduction of newer and more potent agents. Detailed international guidelines exist that provide advice for the optimal care of CHB patients. Despite that, several topics such as optimal treatment indication, choice of treatment type, and the discontinuation of nucleos(t)ide analogue therapy remain controversial, as relevant recommendations and expert opinions often vary widely. This review addresses these topics in more detail aiming to provide some clarifications taking into account the most recent data from the available literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85. The most recent scientific guidelines for the management of chronic hepatitis B.

    Article  Google Scholar 

  2. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis. 2006;26:130–41.

    Article  CAS  PubMed  Google Scholar 

  3. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167–78.

    Article  CAS  PubMed  Google Scholar 

  4. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Ann Intern Med. 2009;150:104–10.

    Article  PubMed  Google Scholar 

  5. Liaw YFKJ, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.

    Article  PubMed  Google Scholar 

  6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    Article  PubMed  Google Scholar 

  7. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol. 2008;14:6902–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118–29.

    Article  CAS  PubMed  Google Scholar 

  9. Papatheodoridis GV. Hepatitis B, virus treatment: which patients can have treatment deferred? Clin Liver Dis. 2013;2:15–7. A detailed commentary on the treatment indications and the dilemmas for patients with grey-zone ALT and HBV DNA levels.

    Article  Google Scholar 

  10. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240–8. The only randomized trial in HBeAg-positive immunotolerant patients which shows that oral antiviral therapy can achieve inhibition of viral replication but offers very low rates of HBeAg seroconversion.

    Article  CAS  PubMed  Google Scholar 

  11. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    Article  CAS  PubMed  Google Scholar 

  12. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology. 2010;51:435–44.

    Article  PubMed  Google Scholar 

  13. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–21.

    Article  CAS  PubMed  Google Scholar 

  14. Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–7.

    Article  CAS  PubMed  Google Scholar 

  15. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.

    Article  PubMed  Google Scholar 

  16. Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225–34.

    Article  CAS  PubMed  Google Scholar 

  17. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376–84.

    Article  PubMed  Google Scholar 

  18. Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57:196–202. A comprehensive review on the optimal follow-up of HBeAg-negative chronic hepatitis B patients with normal ALT who represent the largest subgroup of patients with chronic hepatitis B virus infection.

    Article  PubMed  Google Scholar 

  19. Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos(t]ide analogues for treatment of chronic hepatitis B. Curr Hepat Rep. 2010;9:91–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676–83. An interesting study showing the slow decline of HBsAg levels during oral antiviral therapy.

    Article  CAS  PubMed  Google Scholar 

  21. Kranidioti H, Manolakopoulos S, Khakoo SI. Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. Ann Gastroenterol. 2015;28:173–81.

    PubMed  PubMed Central  Google Scholar 

  22. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000;32:635–9.

    Article  CAS  PubMed  Google Scholar 

  23. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57–63.

    Article  CAS  PubMed  Google Scholar 

  24. Reijnders JG, Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: is the glass half full or half empty? Hepatology. 2013;58:1885–7.

    Article  CAS  PubMed  Google Scholar 

  25. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–6.

    Article  CAS  PubMed  Google Scholar 

  26. Byun KS, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol. 2005;20:1838–42.

    Article  CAS  PubMed  Google Scholar 

  27. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–21.

    Article  CAS  PubMed  Google Scholar 

  28. Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, et al. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8, e68568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yoon SK, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005;48:341–9.

    Article  CAS  PubMed  Google Scholar 

  30. Wang L, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, et al. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298–304.

    Article  CAS  PubMed  Google Scholar 

  31. Chien RN, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther. 2006;11:947–52.

    CAS  PubMed  Google Scholar 

  32. Yu F, Wang Y, Yuan S, Ma J, Ma N, Zhang X, et al. Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B. Scand J Gastroenterol. 2013;48:745–51.

    Article  CAS  PubMed  Google Scholar 

  33. Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011;26:456–60.

    Article  PubMed  Google Scholar 

  34. Ha M, Zhang G, Diao S, Lin M, Sun L, She H, et al. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol. 2012;157:285–90.

    Article  CAS  PubMed  Google Scholar 

  35. Paik YH, Kim JK, Kim DY, Park JY, Ahn SH, Han KH, et al. Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. J Korean Med Sci. 2010;25:882–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, et al. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol. 2013;19:300–4.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology. 2012;143:629–36. e621.

    Article  CAS  PubMed  Google Scholar 

  38. Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888–96. An interesting study evaluating the rates of virological remission after discontinuation of oral antiviral therapy in HBeAg-negative chronic hepatitis B.

    Article  CAS  PubMed  Google Scholar 

  39. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249–57.

    Article  CAS  PubMed  Google Scholar 

  40. Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014;61:515–22.

    Article  CAS  PubMed  Google Scholar 

  41. Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Spyros I. Siakavellas declares no conflict of interest.

George V. Papatheodoridis has served as an advisor/consultant/lecturer for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche, has received research grants from Bristol-Myers Squibb, Gilead, and Roche, and has served on the Data Safety Management Board for Gilead.

Human and Animal Rights and Informed Consent

This article is a review and does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Athens University Medical School, Laiko General Hospital, AgiouThoma 17, 11527, Athens, Greece

    Spyros I. Siakavellas & George V. Papatheodoridis

Authors
  1. Spyros I. Siakavellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George V. Papatheodoridis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George V. Papatheodoridis.

Additional information

This article is part of the Topical Collection on Hepatitis B

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Siakavellas, S.I., Papatheodoridis, G.V. Controversial Issues in Current Treatment of Chronic HBV Infection. Curr Hepatology Rep 14, 164–170 (2015). https://doi.org/10.1007/s11901-015-0268-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-015-0268-4

Keywords

Search

Navigation